Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628672 | 0.87 | TSHR (0.60) | TSHRRAB9AALDH1A1CA12CA1 | |
| SCHEMBL23817389 | 0.87 | RAB9A (0.50) | TSHRRAB9ACES2CES1ALDH1A1 | |
| SCHEMBL1997075 | 0.86 | TSHR (0.60) | TSHRRAB9ACES2CES1ALDH1A1 | |
| SCHEMBL5247862 | 0.86 | TSHR (0.57) | TSHRRAB9AALDH1A1CA12CA1 | |
| SCHEMBL7222675 | 0.86 | TSHR (0.53) | TSHRRAB9AALDH1A1CA12CA1 | |
| SCHEMBL187298 | 0.84 | CA12 (0.70) | TSHRRAB9AALDH1A1CA12CA1 | |
| SCHEMBL11695717 | 0.84 | TSHR (0.52) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL927276 | 0.84 | CA12 (0.70) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL539982 | 0.83 | MAP2K1 (0.55) | TSHRALDH1A1CA12CA1CA2 | |
| SCHEMBL751617 | 0.83 | LMNA (0.54) | TSHRRAB9AALDH1A1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113429563-B | Application of selective laser sintering by taking polyether-ether-ketone prepared by solvent as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113429562-B | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113321800-B | Application of selective laser sintering by taking polyether-ether-ketone prepared from tetramethyl guanidine tetrafluoroborate as raw material | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-113429532-B | Application of polyether-ether-ketone prepared from 1-butyl-3-methylimidazole bromide in selective laser sintering | 江汉大学 | 2023-05-23 | — | — | CN | claimed |
| CN-114865080-A | Lithium ion battery electrolyte and lithium ion battery | 香河昆仑新能源材料股份有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-113429562-A | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113429563-A | Application of selective laser sintering by using polyether-ether-ketone prepared by adopting solvent as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113429532-A | Application of selective laser sintering by using polyether-ether-ketone prepared from 1-butyl-3-methylimidazole bromine salt as raw material | 江汉大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113321800-A | Application of selective laser sintering by using polyether-ether-ketone prepared from tetramethylguanidine tetrafluoroborate as raw material | 江汉大学 | 2021-08-31 | — | — | CN | claimed |
| CN-108034047-B | Application of selective laser sintering by taking polyether-ether-ketone as raw material | 江汉大学 | 2021-06-22 | — | — | CN | claimed |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2017-06-08 | — | — | US | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-12577217-B2 | 15-PGDH inhibitor | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-5753682-A | Imidazole lipoxygenase inhibitors | PFIZER INC. (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0703913-B1 | IMIDAZOLES AS LIPOXYGENASE INHIBITORS | PFIZER (US) | 1997-06-11 | — | — | EP | disclosed |
| EP-0703913-A1 | IMIDAZOLE LIPOXYGENASE INHIBITORS | PFIZER (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994029299-A1 | IMIDAZOLE LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028345-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, TEC | TSHR 935/4885RAB9A 2655/4885CES2 2447/4885 |
| US-12577217-B2 | 15-PGDH inhibitor | PTGDR, ADH1A, ADRA1A | TSHR 413/4885RAB9A 1847/4885CES2 1604/4885 |
| US-20170158666-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | TSHR 3754/4885RAB9A 3546/4885CES2 4241/4885 |
| US-20260028346-A1 | BTK DEGRADER AND USE THEREOF | BTK, SYK, LYN | TSHR 1144/4885RAB9A 2415/4885CES2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.